Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has announced the acceptance of four abstracts for the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place from October 23-25, 2024, in Barcelona, Spain. The presentations will feature promising data on casdatifan, a potential best-in-class HIF-2α inhibitor for treating clear cell renal cell carcinoma (ccRCC).
The oral presentation will cover findings from around 30 patients in the 100 mg daily monotherapy expansion cohort of the ARC-20 Phase 1/1b study, detailing safety and efficacy metrics, including objective response rates and progression rates. Additional data from a 50 mg monotherapy cohort will also be presented.
Terry Rosen, Ph.D., CEO of Arcus, expressed excitement about sharing the first clinical efficacy data from the ARC-20 study, emphasizing the unique profile of casdatifan in ccRCC and its potential across other tumor types. He noted plans to initiate a Phase 3 study in the first half of 2025.
Arcus is pursuing a comprehensive development strategy for casdatifan in both first-line and post-anti-PD-1 settings, including a combination with cabozantinib. The upcoming PEAK-1 study will compare this combination against cabozantinib alone in metastatic ccRCC patients previously treated with anti-PD-1 therapy, focusing on progression-free and overall survival.
Investors can join a conference call on October 24, 2024, at 5:00 AM PT / 8:00 AM ET using Conference ID: 595409. The live webcast and slide presentation will be available on the Arcus website, with a replay following the event.
Abstracts to Be Presented:
- Casdatifan in Previously Treated ccRCC
Session Type: Oral Plenary Session
Date/Time: 10/24/2024, 10:54 AM CEST - HIF-2α Inhibition by Casdatifan
Session Type: Molecular Targeted Agents
Date/Time: 10/23/2024, 12:00 PM CEST - PK/PD Relationship for Casdatifan
Session Type: Molecular Targeted Agents
Date/Time: 10/23/2024, 12:00 PM CEST - AB801 AXL Inhibitor Efficacy
Session Type: New Drugs
Date/Time: 10/23/2024, 12:00 PM CEST
About Arcus Biosciences
Founded in 2015, Arcus Biosciences develops innovative cancer treatments in collaboration with industry partners and healthcare professionals. The company is advancing several investigational drugs targeting key biological pathways. For more information, visit www.arcusbio.com.
